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Background: Development of cancer therapeutics partially depends upon selection of appropriate animal models.
Therefore, improvements to model selection are beneficial.
Results: Forty-nine human tumor xenografts at in vivo passages 1, 4 and 10 were subjected to cDNA microarray analysis
yielding a dataset of 823 Affymetrix HG-U133 Plus 2.0 arrays. To illustrate mining strategies supporting therapeutic studies,
transcript expression was determined: 1) relative to other models, 2) with successive in vivo passage, and 3) during the
in vitro to in vivo transition. Ranking models according to relative transcript expression in vivo has the potential to
improve initial model selection. For example, combining p53 tumor expression data with mutational status
could guide selection of tumors for therapeutic studies of agents where p53 status purportedly affects efficacy
(e.g., MK-1775). The utility of monitoring changes in gene expression with extended in vivo tumor passages was
illustrated by focused studies of drug resistance mediators and receptor tyrosine kinases. Noteworthy observations
included a significant decline in HCT-15 colon xenograft ABCB1 transporter expression and increased expression of the
kinase KIT in A549 with serial passage. These trends predict sensitivity to agents such as paclitaxel (ABCB1 substrate)
and imatinib (c-KIT inhibitor) would be altered with extended passage. Given that gene expression results indicated
some models undergo profound changes with in vivo passage, a general metric of stability was generated so models
could be ranked accordingly. Lastly, changes occurring during transition from in vitro to in vivo growth may have
important consequences for therapeutic studies since targets identified in vitro could be over- or under-represented
when tumor cells adapt to in vivo growth. A comprehensive list of mouse transcripts capable of cross-hybridizing with
human probe sets on the HG-U133 Plus 2.0 array was generated. Removal of the murine artifacts followed by pairwise
analysis of in vitro cells with respective passage 1 xenografts and GO analysis illustrates the complex interplay that each
model has with the host microenvironment.
Conclusions: This study provides strategies to aid selection of xenograft models for therapeutic studies. These data
highlight the dynamic nature of xenograft models and emphasize the importance of maintaining passage consistency
throughout experiments.
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Xenograft models remain a cornerstone technology in
the development of anti-cancer agents [1]. The ability of
immunocompromised rodents to support the growth of
human tumors provides an invaluable transition between
in vitro testing, pre-clinical development and clinical trials.
For decades, data from xenograft models has informed
development decisions with respect to dosing schedules,
pharmacokinetics/pharmacodynamics (PK/PD) and po-
tential toxicities. Yet several challenges remain, including
understanding the extent to which well-characterized
xenograft models replicate the biology and growth charac-
teristics of patient disease. Furthermore, with the para-
digm shift towards agents with specific molecular targets
and personalized medicine, a comprehensive molecular
profile for xenograft models may be essential for success-
ful in vivo evaluation. To this end, considerable resources
are being applied to the generation of novel xenograft
models combined with molecular profiling of existing
models [2].
Within the Developmental Therapeutics Program (DTP)
of the National Cancer Institute, the primary in vitro assay
used to detect potential anti-cancer activity is the NCI-60
cell line screen. To date, this panel of human tumor lines
has been used to evaluate almost one hundred thousand
pure compounds and approximately fifty thousand natural
product extracts. Many of these cell lines will grow as
subcutaneous xenografts, thus cell lines sensitive to an
agent in vitro were often subjected to further analyses in
xenografts derived from those cell lines. The NCI-60
panel has been extensively molecularly characterized, with
data available for gene expression, DNA variation (muta-
tion and SNPs), protein expression, DNA methylation,
microRNA expression and metabolomics (http://dtp.
cancer.gov/mtargets/mt_index.html) [3-9]. The COM-
PARE algorithm (http://dtp.nci.nih.gov/docs/compare/
compare.html) allows investigators to correlate NCI-60
drug activity profiles with all other open agents in the
database and with molecular characteristics of the cells
[10]. While the in vitro grown cells have been character-
ized, the corresponding subcutaneous xenografts had not.
However, other studies have succeeded in molecular pro-
filing of other xenografts [2,11,12]. These predominantly
cDNA and tissue-array based studies lack the potential for
retrospective cross-platform analysis that underscores the
NCI-60 cell line set.
The MicroXeno Project was initiated to generate
genome-wide cDNA microarray data for all subcutaneous
xenograft models currently used within the DTP. Compre-
hensive transcriptomic analysis will help address questions
such as: Can expression of molecular target[s] help inform
model selection for a given agent or target, or to what ex-
tent and by what manner do specific cell line tumors adapt
during prolonged growth in vivo? The work presented hereprovides a reference dataset that can be used to confirm
the genetic characteristics and stability of models going
forward. This ongoing project will ultimately encompass
over 100 models, with data from cell lines and successive
xenograft passages. The panel includes tumor cell lines
from diverse histological origins including leukemia/
lymphoma, non-small cell lung, colon, CNS, melanoma,
ovarian, renal, prostate, liver, gastric, head and neck, pan-
creatic, and breast cancer. It also includes, but is not limited
to, many of the cell lines in the NCI-60 panel (http://dtp.
cancer.gov/docs/misc/common_files/cell_list.html).
Here we describe the procedures and quality control
criteria used to derive MicroXeno release 1.0. The study
utilizes Affymetrix HG-U133 Plus 2.0 arrays, capable
of identifying more that 30,000 human transcripts
from >54,000 probe sets [13]. The current release en-
compasses 49 experiments with each consisting of data
from the originating cell lines and the resulting xenografts
at passages 1, 4 and 10 (P1, P4, P10). In addition, we detail
several approaches to utilize the data to predict possible
biological outcomes. We propose that this dataset [and
subsequent releases] will improve selection and execution
of subcutaneous xenograft experiments during the
evaluation of cancer therapeutics. As this study is based
primarily on lines from the NCI-60 panel, the potential
also exists for integration with other NCI-60 datasets
(mutational analysis, protein arrays, etc.). Rapid dissemin-
ation of this data will also permit the extramural commu-
nity to perform meta-analyses in support of their own
in vivo studies.
Results and discussion
This study focused on generating pan-genomic cDNA
microarray data for diverse xenograft models from the
time of initial implantation to the tenth passage using the
Affymetrix HG-U133 Plus 2.0 array. Each experiment
comprised the originating in vitro cell lines [designated
P0] along with tumor samples from in vivo passages 1, 4
and 10. For each in vivo passage, five tumors were har-
vested. The 49 human xenograft experiments contained
within this release led to the generation of 844 arrays.
Table 1 details the specific cell lines along with tumor
types, histology, host strain and any special growth
requirements or irregularities.
Microarray data quality control
Multiple layers of quality control criteria were applied to
the dataset. First, the 844 CEL files (including P4 and
P10 of SF-268 and SF-539) were visually inspected using
DChip (http://www.hsph.harvard.edu/cli/complab/dchip/)
to identify arrays with structural defects. Significant physical
issues were identified in one MDA-MB-231 T P4 sample,
which was removed. Next, .CEL files were uploaded and
analyzed en masse using the QC tools contained within
Table 1 Tumor cell lines, host mice, protocol variances
Tumor typea Tumor name Histology Mouse strain Comments
Breast MCF7b Adenocarcinoma nu/nu NCr 2 samples P0, 4 samples P1
MDA-MB-231 T Adenocarcinoma, from mouse nu/nu NCr 2 samples P0
Cervical HeLa-Luc Adenocarcinoma nu/nu NCr 2 samples P0
CNS SF-268c Anaplastic Astrocytoma NOD.SCID/NCr 2 samples P0, P4 and P10 are mouse
SF-539c Glioblastoma NOD.SCID/NCr 2 samples P0, P4 and P10 are mouse
U251 Glioblastoma nu/nu NCr 2 samples P0
Colon COLO 205 Adenocarcinoma nu/nu NCr
HCC-2998 Carcinoma nu/nu NCr
HCT-116 Carcinoma nu/nu NCr
HCT-15 Adenocarcinoma nu/nu NCr
HT-29 Adenocarcinoma, GR III nu/nu NCr
KM12 Adenocarcinoma nu/nu NCr
SW-620 Adenocarcinoma nu/nu NCr
Gastric GTL 16 Adenocarcinoma nu/nu NCr 2 samples P0
Leukemia/ AS283 AIDs related Burkitts Lymphoma SCID/NCr 2 samples P0
Lymphoma CA46 B Lymphocyte Burkitts Lymphoma SCID/NCr 2 samples P0
CCRF-CEM Acute Lymphoblastic Leukemia (T-ALL) SCID/NCr
HL-60(TB) Promyelocytic Leukemia SCID/NCr 3 samples P5 substituted for P4; 4 P0 samples
K-562 Chronic Myelogenous Leukemia SCID/NCr 5 samples P5 substituted for P4, 4 samples P10
MOLT-4 Acute Lymphoblastic Leukemia SCID/NCr
SR Large Cell, Immunoblastic SCID/NCr
Liver HuH-7 Differentiated Hepatocellular Carcinoma nu/nu NCr 2 samples P0
Lung A549 Adenocarcinoma nu/nu NCr
A549/Asc-1 Adenocarcinoma nu/nu NCr 3 samples P4, 2 samples P0
EKVX Adenocarcinoma SCID/NCr 2 samples P0
HOP-62 Adenocarcinoma nu/nu NCr 4 samples P1
HOP-92 Large Cell, undifferentiated nu/nu NCr
NCI-H226 Squamous Carcinoma nu/nu NCr 2 samples P1
NCI-H23 Adenocarcinoma, NSCLC nu/nu NCr 2 samples P0
NCI-H460 Large Cell Carcinoma nu/nu NCr
NCI-H522 Adenocarcinoma nu/nu NCr 2 samples P0
Melanoma A375 Metastatic Malignant Melanoma nu/nu NCr 2 samples P0
COLO 829 Malignant Melanoma nu/nu NCr 2 samples P0
LOX IMVI Malignant Amelanocytic Melanoma nu/nu NCr 2 samples P0
M14 Adenocarcinoma nu/nu NCr 2 samples P0
MALME-3 M Malignant Melanoma nu/nu NCr 2 samples P0, 4 samples P4
MDA-MB-435 Adenocarcinoma nu/nu NCr 2 samples P0, 3 samples P10
MDA-Nd HER2/ERB2 transfectant of MDA-MB-435 nu/nu NCr 2 samples P0
UACC-62 Malignant Melanoma nu/nu NCr
Ovarian CP70 Carcinoma nu/nu NCr 2 samples P0
OVCAR-3 Adenocarcinoma nu/nu NCr 2 samples P0
OVCAR-5 Carcinoma nu/nu NCr 2 samples P0
Pancreatic AsPC-1 Adenocarcinoma nu/nu NCr 2 samples P0
Prostate PC-3 Adenocarcinoma Male nu/nu NCr 2 samples P0
PC-3/Me Metastatic PC-3 subline Male nu/nu NCr
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Table 1 Tumor cell lines, host mice, protocol variances (Continued)
Renal 786-0 Adenocarcinoma nu/nu NCr
CAKI-1 Renal Cell Carcinoma nu/nu NCr 2 samples P0
RXF 393 Poorly Differentiated Hypernephroma nu/nu NCr
SN12C Carcinoma nu/nu NCr 2 samples P0
aTumor cells derived from the 4th in vitro passage were innoculated subcutaneously into mice. Tumors were passaged 10 consecutive times in mice. At passages
1, 4, and 10 (P1, P4, P10, respectively), 5 tumors were harvested, cut into small pieces and flash frozen in liquid nitrogen. Samples were then processed as
described in Methods. For comparative purposes, 3 samples of the in vitro cultivated cells at passage 4 (P0) were also prepared for microarray analysis.
b3 mg/kg Q7D SC Estradiol.
cMatrigel 18.1 mg/mL P1 only.
dHER2/ERBB2 transfectant of MDA-MB-435.
ePC3 subline isolated from liver metastasis in mice.
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demonstrated one replicate from the PC-3 P10 had con-
trol probe errors and it was excluded (Figure 1A). The
hybridization was repeated using the original PC-3 P10
RNA sample on a new chip that yielded satisfactory results
and was included in further analyses. Lastly, principal
component analysis (PCA) was used to identify outliers.
For example, results shown in Figure 1B identify one
population of arrays segregated from the primary com-
ponent. Closer inspection identified these .CEL files as
passages 4 and 10 of SF-268 and SF-539. This finding
suggested a conserved problem with late passage for
these lines. We then investigated whether displacement
of tumor cells by an outgrowth of mouse cells was respon-
sible for the observed effects. Results from endpoint PCR
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Figure 1 Study design and quality control. A) Control probe signal prof
The single outlier (PC-3 P10 100913) is highlighted. B) 3D principal compon
outliers representing P4 and P10 passages for SF-268 and SF-539 glioma lin
using Genespring GX11 (Agilent, Santa Clara, CA). C) Endpoint PCR of geno
mouse or human-specific PTGER2 primers [see Methods]. Genomic DNA fro
included as positive controls, NTC = no template control. Data is representadirected against PTGER2 [14] showed the first in vivo pas-
sage of SF-268 and SF-539 tumors contained both mouse
and human genomic DNA as expected, but all tumors
harvested from 4th and 10th serial passages were devoid
of human genomic DNA. The SF-268 and SF-539 models
differed from others in the study in that they utilized
Matrigel® to initially establish tumor growth in passage 1
and they were implanted into NOD.SCID/NCr mice since
growth in athymic nu/nuNCr mice was unsuccessful. It is
recognized that NOD.SCID/NCr mice have a propensity
for spontaneous tumor formation [15] and also it is
reasonable to speculate that Matrigel® (a growth-factor
rich gel secreted by EHS (Engelbreth-Holm-Swarm) mouse
sarcoma cells) may encourage spontaneous host cell out-
growth. This emphasizes the need for routine monitoring
of mouse outgrowth especially when Matrigel®, and possiblySF-268 P4, P10
SF-539 P4, P10
Mouse Specific PCR Primers
SF-539 SF-268
P1      P4     P10 P1      P4     P10
iles were generated for 844 Affymetrix HG-U133 Plus 2.0 array .CEL files.
ent analysis (PCA) was performed on all .CEL files; a population of
es is shown in red. Control probe profiles and 3D PCA were generated
mic DNA from SF-539 and SF-268 tumors at P1, P4 and P10 using
m B16F10 [B16, Mouse] and LnCAP [LC, human] cell lines were
tive of all tumors processed from these xenografts.
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outgrowth was not a problem for the remaining models,
this phenomenon should be an important consideration for
studies involving serial passage of tumor fragments over
extended periods of time. In light of these results, P4 and
P10 samples for SF-268 and SF-539 were not included in
this data release.
Hierarchical clustering QC
All experiments were subjected to hierarchical clustering
to confirm similarity in microarray signatures for cell lines
and subsequent xenograft passages. Fold-change data
[100-fold cut-off] for each parameter was used to generate
the hierarchical cluster shown in Additional file 1. This
analysis confirmed that for the majority of experiments,
the originating cell lines and subsequent in vivo passages
clustered together. However, P10 data for CAKI-1, SN12C
and RXF 393 renal lines were shown to cluster together,
suggesting a high degree of similarity between these
samples (Additional file 2A). The identity of these tumors
was confirmed by repeating the Identifiler® STR analyses.
Thus, the clustering of these P10 renal tumors of distinct
cell line origins had a biological basis and was not the
result of technical errors. Other exceptions involved the
co-clustering of MDA-MB-435 and MDA-N (Additional
file 2B) along with a similar trend for A549 and A549/
Asc-1 (Additional file 2C). These observations were antici-
pated given that MDA-N is derived from MDA-MB-435
and A549/Asc-1 is a tumorigenic clone of A549. Add-
itionally, two breast cancer cell lines (MCF7 and MDA-
MB-231 T) did not cluster together nor did three ovarian
lines (OVCAR-3, CP70, and OVCAR-5) (Additional file
2D and E). Closer scrutiny provides a plausible explan-
ation given these lines differ significantly within their
categories. Specifically, MCF7 is an estrogen-dependent
(ER+) tumor whereas MDA-MB-231 T is triple negative
(negative for estrogen receptor, progesterone receptor,
Her2/neu). Similarly, CP70 and OVCAR-5 are ovarian
carcinomas whereas OVCAR-3 is an adenocarcinoma.
OVCAR-3 is also ER + while OVCAR-5 is ER negative
and CP70 is a cisplatin-resistant subline of A2780. Fol-
lowing quality control, the final dataset comprised 47
complete experiments and 2 partial experiments (P0 and
P1 for SF-268 and SF-539) for a total of 823 arrays.
Monitoring changes in transcript expression
The central goal of this study was to ascertain expression
levels for any given transcript across all in vivo models
and with successive passage. To this end, normalized gene
expression data were generated for all 192 conditions [see
Additional file 3, txt file should be copied into EXCEL or
other spreadsheet application to view]. Throughout the
study, when multiple probe sets were present for the
same transcript, the Jetset methodology [16] was usedto select the most robust candidate. Data for four example
probe sets; 205225_at (ESR1, estrogen receptor alpha),
206426_at (MLANA, melan-A), 201839_s_at (EPCAM,
epithelial cell adhesion molecule), and 201746_at (TP53,
p53) at P1, P4 and P10 are plotted in Figure 2. Results
showed that MCF7 cells expressed the highest level of
ESR1 across the panel, consistent with their known estro-
gen receptor positive status and their absolute dependence
on exogenous estradiol for growth in mice. Furthermore,
ESR1 expression was shown to increase modestly with
passage, suggesting serially passaged tumors remain a
valid target for estrogen receptor antagonists. MLANA
(Melan-A) is a melanoma-restricted antigen and results
show expression to be limited primarily to the melanoma
cell lines. MLANA expression was relatively consistent
with passage, apart from UACC-62 where levels modestly
increase at P10. Similarly, EPCAM is highly expressed
on many epithelial cells and results show considerable
variation in mRNA expression levels even between epi-
thelial lines. While most tumors had stable expression
of EPCAM from P1 to P10, there were a few models with
notable changes including A549, CaKi-1 and NCI-H460.
The final example, TP53/p53 serves to show the value
of integrating relative expression data with pre-existing
genetic information. This tumor suppressor and master
regulator of the cell cycle is frequently mutated or deleted
in tumors [17,18]. This analysis confirmed the relative lack
of p53 expression in p53-null HL60 cells. However, there
was considerable variability in levels of expression for
models with mutant p53. This information could be useful
for studies of agents targeting cells with mutant/deleted
p53 e.g., the Wee1 inhibitor MK-1775 or mutant p53
oncolytic adenovirus [19,20]. Overall, this analysis serves
to illustrate the potential of these data within therapeutic
studies and provide evidence that mRNA expression can
change markedly with in vivo passage.
Another approach to data mining involves plotting the
extent of change in expression with passage. To exemplify,
analyses were performed on two groups of therapeutically
relevant transcripts, those involved in drug resistance and
those coding for select receptor tyrosine kinases (RTKs).
For resistance genes, expression relative to other models
at P1 was plotted (Figure 3A) along with the change in ex-
pression from P1 to P10 (Figure 3B). Several noteworthy
trends were evident. For HCT-15, a highly MDR drug-
resistant cell line in culture, expression of the multidrug
transporter ABCB1 [MDR1] was the highest relative to
other lines at P1. However by P10, the expression had de-
clined to that comparable to other tumors. This suggests
HCT-15 tumors may acquire sensitivity to agents such as
doxorubicin, paclitaxel and other MDR sensitive agents
with serial in vivo passage [21]. This finding is confirmed
by in vivo efficacy data for paclitaxel against subcutane-





































Figure 2 Transcript expression relative to other models and with passage. Log2 normalized gene expression values at passage 1, 4 and 10
plotted for four probe sets; 205225_at (ESR1, estrogen receptor alpha), 206426_at (MLANA, melan-A), 201839_s_at (EPCAM, epithelial cell adhesion
molecule), and 201746_at (TP53, p53). The p53 status is shown for 201746_at as wild type (WT), mutant (MUT) or absent (NULL).
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Figure 3 Change in expression from P1 to P10 for a subset of transcripts involved in drug resistance. A) Log2 normalized expression
values for each transcript in all models at P1. B) Change in log2 normalized expression for each transcript in all models from P1 to P10. For each
probe set, entries are formatted where red is the highest value, green is the lowest and the median is black.
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P1 and P8 tumors to paclitaxel treatment were observed.
The P1 tumors showed progressive growth in spite of
paclitaxel therapy (Additional file 4A). In contrast, the
P8 tumors responded to treatment with total growth inhib-
ition (Additional file 4B). Comparison of tumor weights be-
tween the P8 vehicle and P8 paclitaxel-treated mice showed
statistically significant differences at days 22, 26 and 29 with
p values of 0.0004, 0.001, and 0.0001, respectively. In
contrast, there was no difference between the P1
vehicle-treated and paclitaxel-treated groups at any time
point. These data support the conclusion that HCT-15
human colon tumor xenografts acquire paclitaxel sensitiv-
ity during serial in vivo passage.
Expression of microsomal glutathione S-transferase
(MGST) has been shown to confer resistance to cisplatin
[22]. In this analysis, expression of MGST1 [224918_x_at]
increased with passage in several cell lines such as LOX
IMVI and NCI-H226. Given the general trend toward in-
creased expression from P1 to P10, it could be surmised
that increased resistance would be observed in serially
passaged tumors. This observation is consistent with our
data, where evaluation of cisplatin in subcutaneous LOX
IMVI xenografts showed sensitivity to cisplatin declines
with serial in vivo passage. When cisplatin was admin-
istered at the maximum tolerated dose to LOX-IMV1
tumor-bearing mice at P1, P4 and P10, the optimal
percent test/control values were 19%, 41%, and 64%,
respectively. The %T/C is inversely related to the tumor
sensitivity so the greater the tumor response the lower
the %T/C. A %T/C of 40% or lower is indicative of anti-
tumor activity [23]. Thus, as predicted by the changes in
MGST1 relative expression in LOX IMV1 tumors with
serial in vivo passage, P1 tumors were highly sensitive
while the P10 tumors were not. The ranking of relative
MGST1 expression levels at P1 shows A549/Asc-1 and
A549 have the greatest and MOLT-4 the lowest MGST1
expression. This suggests cisplatin would be inactive against
A549 tumors and active against MOLT-4 tumors. This is
borne out by in vivo sensitivity testing where MOLT-4 has
a statistically significant reduction in tumor growth in
mice receiving 3.24 mg cisplatin/kg compared to ve-
hicle controls (Additional file 5A) while A549 tumors
do not respond even with an increased cisplatin dose
(6.7 mg/kg) and a smaller initial starting tumor size
(Additional file 5B).
Interestingly, the reverse trend in mRNA expression was
observed in CA46 cells, where MGST1 was downregulated
at P10. Here, although no xenograft data exists to confirm
this, sensitivity to cisplatin could be predicted to increase
with in vivo passage. Lastly increased expression of ABCG2,
a transporter that enhances resistance to mitoxantrone,
daunorubicin and doxorubicin [24] was noted in EKVX
cells from P1 to P10.Results in Figure 4 show a similar analysis focused on a
subset of cancer-related receptor tyrosine kinases. Again,
several trends were evident. For example, PC-3 M cells
expressed the highest relative levels of KDR (VEGFR2;
203934_at) at P1. However, levels declined by P10, an ob-
servation that could have consequences for evaluation of
therapeutics targeting this pathway (e.g., sorafenib). The
melanoma cell lines M14 and MALME-3 M expressed
significant levels of KIT (stem cell factor receptor)
[205051_s_at] relative to other models at P1. With serial
passage, expression of KIT declined slightly in MALME-
3 M by P10 whereas the levels were increased in M14 at
P10. Conversely, A549 cells expressed low levels of KIT
at P1, but expression increased markedly at P10. These
observations may have consequences for experiments
where a c-Kit inhibitor (e.g., imatinib) is being evaluated.
A general metric of model stability
The prior analysis suggested that significant changes in
transcript expression occurred in several models from
P1 to P10. Therefore, we sought a general metric of stability
for each xenograft model. To achieve this, the number of
transcripts showing >3-fold increase or >3-fold decrease
(p < 0.05) from P1 to P4 and P1 to P10 was determined
for each of 47 models. We reasoned the higher the stabil-
ity of the model, the smaller the number of transcripts
with changes in expression that would be observed be-
tween passages. Figure 5 illustrates the results of this
analysis, where models such as HL-60 (TB) and MOLT-4
(32 and 66 differentially-expressed transcripts between P1
and P10, respectively) may be defined as highly stable,
whereas NCI-H460 and EKVX tumors are markedly altered
at P10 (1401 and 1696 differentially expressed transcripts
between P1 and P10, respectively) with approximately 50%
of these changes occurring between P1 and P4. From
this analysis it is evident that protracted in vivo growth
profoundly alters the transcriptome for most models.
Generation of a simple metric of stability allows models
to be ranked according to the degree of change. Whether
these changes represent gradual adaptations to growth in
a mouse microenvironment or selection-pressure pro-
moting outgrowth of sub-clones remains to be deter-
mined. However, it is interesting to note that a survey
of genes (CDH1, FN1, KRT19) related to the epithelial-
mesenchymal transition (EMT) identified widespread
changes in several models with passage (results not shown).
Given the recognized effects of EMT on drug sensitivity,
this phenomenon may be worthy of further scrutiny [25].
The cell line to xenograft transition
This dataset can be interrogated to monitor gene ex-
pression changes occurring during the immediate tran-
sition from in vitro to in vivo growth. However, this
analysis is complicated by potential interference from
AB
Figure 4 Change in expression from P1 to P10 for a subset of transcripts coding for receptor tyrosine kinases (RTKs). A) Log2
normalized expression values for each transcript in all models at P1. B) Change in log2 normalized expression for each transcript in all models
from P1 to P10. For each probe set, entries are formatted where red is the highest value, green is the lowest and the median is black.































Figure 5 Ranking model stability. For each model, Genespring GX11 was used to generate a list of differentially expressed transcripts for P1 to
P4 and P1 to P10 [3-fold cut-off, p < 0.05]. The number of differentially regulated transcripts at P1 to P4 and P1 to P10 was then plotted for each
model and results sorted in terms of P1 to P10 [lowest to highest] to generate a measure of model stability.
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ples. Although cell sorting can remove mouse cell contam-
ination [26], an alternative strategy involves identifying
probe sets on the Affymetrix HG-U133 Plus 2.0 array
with the potential to cross-hybridize with mouse mRNA
and excluding these from analysis or flagging them for
additional evaluation. To this end, 5 murine mRNA sam-
ples (mouse universal RNA, B16F10 murine melanomas
and skin from the C57BL/6 mice bearing the tumor, colon
26 murine tumors and skin from the Balb/c mice bearing
the tumor), all performed in triplicate, were applied to the
human Affymetrix HG-U133 Plus 2.0 arrays to generate a
list of cross-hybridizing probe sets [see Methods]. Mouse
RNAs of varied origin were used to provide diversity in
the detection of cross-hybridizing events. Results demon-
strated a total of 7963 probe sets have the potential to
bind mouse mRNA. This includes all possible binding
events ranging from just one of the mouse samples cross
hybridizing to a probe set to the cross hybridization of all
five of the different murine samples. Although relatively
large, this list likely includes probe sets that bind non-
specifically to any cDNA population along with those
mRNAs showing high homology between mouse and
human. Increasing the stringency to 4 and 5 out of 5
murine samples that must bind to a particular probe set
before that probe is excluded from the analysis reduces
the number of probe sets with the potential to cross-
hybridize to murine RNA by 3-fold (to 2614). To provide
flexibility to the investigator the list of transcripts with the
total number of mouse RNA samples found to cross-
hybridize to each probe set is shown in Additional file 6.
As an example of the in vitro to in vivo transition,
Table 2 shows the results from pairwise analysis of prostate
lines (PC-3 and PC-3/M at P0) with their respective P1
xenografts. The 50 highest up-regulated transcripts beforeremoval of the 14 cross hybridizing probe sets are
shown in Table 2, with transcripts showing potential
mouse artifacts identified. Hemoglobin epsilon 1 (HBE1)
[217683_at] is a probable cross-hybridization event that is
important because PC-3 cells are not expected to express
this mRNA. Other genes of note that were removed as a
result of mouse cross-hybridization include SERPINB6,
CXCL1, COL3A1 and ADM. All with the exception of
SERPINB6 are genes of the stromal compartment [27-29].
Removal of the mouse cross-hybridizing probes provides
greater confidence that observations such as increased
expression of IL-8 (202859_x_at), CXCL6 (206336_at),
and ANGPTL4 (223333_s_at) represent genuine adapta-
tions of PC-3/PC3-M cells to in vivo growth. These upreg-
ulated genes point toward activation of pathways involved
in invasion and metastasis [30-32]. Table 3 shows DAVID
gene ontology (GO) analysis for the top 50 up-regulated
genes following removal of the mouse cross-hybridizing
probes. Consistent with the literature [33-37] genes in-
volved in the extracellular matrix (ECM), cell adhesion,
chemotaxis, cytokine, immune response, tumor-host inter-
action and growth factor induced signal transduction were
up-regulated in xenograft tumors relative to those cells
grown in vitro. A spreadsheet of fold-change data for the
P0 to P1 transition (with cross-hybridizing transcripts
noted) is shown in Additional file 7. Similar analyses for
the P0 to P1 transition for the top 50 up-regulated genes
and respective DAVID GO analysis for 9 of the 13 model
classes (see Table 1) can be found in Additional file 8.
Conclusions
The evaluation of cancer therapeutics using xenograft
models is a resource-intensive and time-consuming
endeavor. Currently, molecular profiling with large-scale
genetic, proteomic and metabolic screening technologies
Table 2 Top 50 up-regulated probe sets in the prostate tumor type
Prostate mouse &













231628_s_at SERPINB6 8.169 5 202859_x_at IL8 5.290
216405_at 6.239 5 206336_at CXCL6 5.190
217683_at HBE1 6.171 5 209183_s_at C10orf10 4.672
202859_x_at IL8 5.290 223333_s_at ANGPTL4 4.479
206336_at CXCL6 5.190 211506_s_at IL8 4.451
209183_s_at C10orf10 4.672 201438_at COL6A3 4.328
204470_at CXCL1 4.551 1 212977_at CXCR7 4.231
223333_s_at ANGPTL4 4.479 1570537_a_at 4.170
211506_s_at IL8 4.451 211756_at PTHLH 4.153
201438_at COL6A3 4.328 203828_s_at IL32 3.987
217572_at 4.301 5 241436_at SCNN1G 3.967
212977_at CXCR7 4.231 214157_at GNAS 3.756
1570537_a_at 4.170 221009_s_at ANGPTL4 3.744
211756_at PTHLH 4.153 213711_at KRT81 3.485
203828_s_at IL32 3.987 206300_s_at PTHLH 3.460
241436_at SCNN1G 3.967 1569978_x_at 3.456
215076_s_at COL3A1 3.775 5 211071_s_at MLLT11 3.355
202912_at ADM 3.763 1 201578_at PODXL 3.249
214157_at GNAS 3.756 222449_at PMEPA1 3.230
221009_s_at ANGPTL4 3.744 205199_at CA9 3.189
224344_at COX6A1 3.700 5 201890_at RRM2 3.106
213711_at KRT81 3.485 211030_s_at SLC6A6 3.100
201852_x_at COL3A1 3.483 5 222608_s_at ANLN 3.062
206300_s_at PTHLH 3.460 210095_s_at IGFBP3 3.028
1569978_x_at 3.456 207291_at PRRG4 3.006
211071_s_at MLLT11 3.355 209774_x_at CXCL2 2.979
201578_at PODXL 3.249 211161_s_at COL3A1 2.974
222449_at PMEPA1 3.230 206157_at PTX3 2.970
205199_at CA9 3.189 203373_at SOCS2 2.969
201890_at RRM2 3.106 232381_s_at DNAH5 2.929
211030_s_at SLC6A6 3.100 212143_s_at IGFBP3 2.928
1570107_at 3.091 5 238513_at PRRG4 2.922
222608_s_at ANLN 3.062 201291_s_at TOP2A 2.911
210095_s_at IGFBP3 3.028 202404_s_at COL1A2 2.908
207291_at PRRG4 3.006 205479_s_at PLAU 2.892
209270_at LAMB3 3.002 2 205680_at MMP10 2.803
209774_x_at CXCL2 2.979 217875_s_at PMEPA1 2.797
211161_s_at COL3A1 2.974 230280_at TRIM9 2.763
206157_at PTX3 2.970 227556_at NME7 2.723
203373_at SOCS2 2.969 242517_at KISS1R 2.699
232381_s_at DNAH5 2.929 218691_s_at PDLIM4 2.688
212143_s_at IGFBP3 2.928 219148_at PBK 2.684
238513_at PRRG4 2.922 203691_at PI3 2.684
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Table 2 Top 50 up-regulated probe sets in the prostate tumor type (Continued)
201291_s_at TOP2A 2.911 202998_s_at LOXL2 2.681
202404_s_at COL1A2 2.908 210538_s_at BIRC3 2.669
223484_at C15orf48 2.896 1 229435_at GLIS3 2.667
205479_s_at PLAU 2.892 41469_at PI3 2.649
227140_at INHBA 2.830 1 218355_at KIF4A 2.624
211668_s_at PLAU 2.829 1 214438_at HLX 2.623
205680_at MMP10 2.803 209156_s_at COL6A2 2.597
Left table includes all probe sets, the mouse RNA binding probe sets are identified by the number of cross hybridizing mouse tissue probes that occurred (1-5 see
column 4). Right side of table shows the top 50 human up-regulated probe sets following removal of the mouse component.
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model selection. In this study, cDNA microarray data was
generated for 49 xenograft models routinely used within
the Developmental Therapeutics Program at the NCI. The
majority of these tumor cell lines are available to the
research community through the DCTD Tumor Reposi-
tory (NCI at Frederick) thus allowing this data to provide
guidance for other research studies. Aside from the obvious
utility of ranking models in terms of transcript expression
for specific genes of interest, analysis demonstrated that
prolonged in vivo passage markedly alters the transcrip-
tome of many models. This observation emphasizes the
importance of maintaining passage consistency to minimize
experimental artifacts. Similarly, these findings provide one
explanation for the difficulties reported in reproducingTable 3 DAVID Gene Ontology (GO) functional annotation on
in vitro to in vivo growth
Accession Gene Ontology Term generated from DAVID
analysis of human-RNA-only-binding probe sets
Gene co
GO:0044421 extracellular region part 14
GO:0005615 extracellular space 12
GO:0005576 extracellular region 18
GO:0005578 proteinaceous extracellular matrix 7
GO:0031012 extracellular matrix 7
GO:0009611 response to wounding 7
GO:0019932 second-messenger-mediated signaling 5
GO:0001568 blood vessel development 5
GO:0001944 vasculature development 5
GO:0005581 collagen 3
GO:0048870 cell motility 5
GO:0051674 localization of cell 5
GO:0008009 chemokine activity 3
GO:0006935 chemotaxis 4
GO:0042330 taxis 4
GO:0001501 skeletal system development 5
GO:0042379 chemokine receptor binding 3
GO:0005125 cytokine activity 4
GO:0005201 extracellular matrix structural constituent 3experimental data since the methods for generating test
tumors can impact the study profoundly [38]. These data
are deposited at http://dtp.nci.nih.gov/microxeno/down-
load.html and in the Gene Expression Omnibus (http://
www.ncbi.nlm.nih.gov/geo/) under accessions GSE48433
and GSE49353. All subsequent data releases will be depos-
ited in the same locations.
Methods
Cell lines and mice
All cell lines were obtained from the Division of Cancer
Treatment and Diagnosis Tumor Repository (DTP, Na-
tional Cancer Institute at Frederick, Frederick, MD) or
American Type Culture Collection (ATCC) (Manassas,
Va). In addition, the identities of all cell lines used in thisthe prostate tumor models during their transition from
unt PValue Fold enrichment Benjamini False discovery
rate (%)
4.68E-07 5.33 4.12E-05 5.07E-04
8.91E-07 6.40 3.92E-05 9.65E-04
3.26E-06 3.27 9.55E-05 3.53E-03
1.75E-04 7.99 3.84E-03 0.19
2.63E-04 7.41 4.61E-03 0.28
0.0019 5.10 0.6674 2.70
0.0027 8.22 0.5559 3.96
0.0032 7.89 0.4668 4.58
0.0035 7.70 0.4022 4.99
0.0039 31.30 0.0553 4.11
0.0071 6.30 0.4510 9.91
0.0071 6.30 0.4510 9.91
0.0072 22.88 0.6673 8.26
0.0074 9.66 0.4245 10.41
0.0074 9.66 0.4245 10.41
0.0081 6.06 0.4132 11.24
0.0081 21.48 0.4633 9.29
0.0166 7.20 0.5732 18.13
0.0236 12.24 0.5992 24.90
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(Applied Biosystems). All mice used in the study were ob-
tained from the Animal Production Program (National
Cancer Institute at Frederick, Frederick, MD). All studies
were conducted in an Association for Assessment and
Accreditation of Laboratory Animal Care International
(AAALACi) accredited facility under a protocol approved
by the NCI at Frederick Animal Care and Use Committee.
This facility operates under an Office of Laboratory Animal
Welfare (OLAW) assurance in compliance with the U.S.
Public Health Service Policy on Humane Care and Use
of Animals (1996) and the Guide for the Care and Use
of Laboratory Animals Eighth Edition. PCR primers were
purchased from ABI (Applied Biosystems). Karyotype ana-
lysis and STR genotyping results for most seed lines are
available at http://dtp.cancer.gov/branches/btb/characteri-
zationNCI60.html.
Tumor growth, propagation and sampling
Tumor cells for inoculation were derived from the 4th
in vitro passage from cryopreserved cell stocks. Cells (1 ×
107 cells/0.1 ml/inoculation) were inoculated subcutane-
ously into mice (n = 10 or more mice depending on the
tumor cell line). For comparative purposes, 2–3 samples
of in vitro cultivated cells at passage 4 (same as used for
in vivo implantation) were also prepared for microarray
analysis (P0). When tumors at passage 1 (P1), passage 4
(P4) and passage 10 (P10) reached approximately 500 mg
(10×10 mm), 5 tumors were harvested, cut into small
pieces and flash frozen in liquid nitrogen using pre-chilled
cryovials. Samples were transferred to a −70°C freezer for
holding prior to processing. Serial tumor passage was
achieved by harvesting donor tumor material (n = 2 to 5
donors) at each passage, mincing the tumors (2x2 mm
fragments), pooling the samples and inoculating the
recipients subcutaneously using tumor implant trocars.
Athymic nude mice (athymic NCr-nu/nu) served as the pri-
mary host for most xenograft studies. In several instances
[particularly with human leukemias and lymphomas] it was
difficult to establish and passage tumors in athymic nude
mice. In these instances, SCID/NCr or NOD.SCID/NCr
mice were assessed for suitability. In general, female mice
were used as they are less aggressive, easily group-housed
and are routinely used in xenograft experiments. Male mice
were used for prostate tumors (PC-3, PC-3/M). Two tu-
mors (SF-268 and SF-539) required the use of Matrigel™
(Collaborative Research, Bectin Dickinson, Bedford, Ma)
during the initial tumor cell inoculation to achieve progres-
sive tumor growth. Finally, in those instances where
hormone effects on tumor growth are important (e.g.,
estradiol-dependent breast cancers) mice were supplemented
with estradiol (up to 3 mg/kg) administered subcutane-
ously once weekly to maintain progressive tumor growth.
Exceptions to the standard protocol are noted in Table 1.Comparison of HCT-15 sensitivity to paclitaxel at early
and late in vivo passage
In vivo antitumor activity assays were performed with
six-week-old female athymic nude mice (Animal Produc-
tion Program, Frederick, MD). Forty mice were each im-
planted subcutaneously with 1x107 HCT-15 human colon
cancer cells (DCTD Repository, Frederick, MD). Thirty of
these passage 1 (P1) tumor-bearing mice were randomized
into 2 groups (n = 20/vehicle control group and 10/treated
group) and the remaining tumors were used to serially
passage the tumors. For this, tumors were harvested from
donor mice, cut into fragments of 2–3 mm and the result-
ing fragments were implanted subcutaneously into recipi-
ent mice using a tumor implant trocar. This process was
repeated when the tumors reached 500–750 mg until the
tumors reached their eighth in vivo passage (P8). At
P8, tumor-bearing animals were randomized into 2
groups (n = 18/vehicle control group and 9/treated
group). At P1 and P8 the vehicle control groups re-
ceived 12.5% cremaphor/12.5% ethanol/75% saline
while the treated group received 10 mg paclitaxel/kg.
Both treatments were administered intravenously (IV)
once daily for 5 days (QDx5) using a standard dosing
volume of 10 ml/kg body weight. Tumor growth was
monitored by caliper measurements, and tumor weights
were calculated as: [tumor length in mm× (tumor width2
in mm)]/2 = weight in mg (1). Tumor measurements were
collected every 3 to 4 days throughout the course of the
study. Student’s t-test was used to assess the significance
in response of the paclitaxel treated animals to the corre-
sponding controls with significance set at a p value of 0.05
or less. The studies were terminated 12 – 15 days after the
last drug dose.
In vivo sensitivity testing of MOLT-4 and A549 xenografts
to cisplatin treatment
In vivo antitumor activity assays were performed with
six-week-old female athymic nude mice (Animal Produc-
tion Program, Frederick, MD). MOLT-4 and A549 tumors
were established in cohorts of mice for evaluation of
cisplatin sensitivity. When MOLT-4 tumors reached a
median of 150 mg the mice were randomized into vehicle
control (n = 20) and cisplatin treated groups (n = 10). The
vehicle control group received 0.9% saline while the
cisplatin was administered at 3.24 mg/kg. When A549
tumors reached a median of 110 mg the mice were ran-
domized into vehicle control (n = 15) and cisplatin-treated
groups (n = 6). The vehicle control group received 0.9%
saline while the cisplatin was administered at 6.7 mg/kg.
All treatments were administered intraperitoneally (IP) at
one dose per day every fourth day for a total of 3 doses
(Q4Dx3) using a standard dosing volume of 10 ml/kg
body weight. Tumor growth was monitored as noted
above. The studies were terminated when control tumor
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whichever occurred first.
Tumor homogenization and RNA Isolation
Frozen xenograft tumor specimens were removed from
the freezer and kept in liquid nitrogen. Tumors were cut
into smaller pieces using a pill cutter pre-chilled by
submersion into liquid nitrogen. A tumor fragment was
placed into the pill cutter and quickly cut into smaller
pieces (approximately 10–25 milligrams each). The tumor
samples were homogenized in RLT-ME buffer (Qiagen,
Germantown, MD) using a single 5 mm steel bead per
sample in a Tissuelyser (Qiagen, Germantown, MD) for
two minutes at 28 Hz. The volume of RLT-ME buffer for
each sample was calculated using a standard formula of
20 μL RLT-ME per mg of tissue. Samples were incubated
at RT for 10 min after homogenization following which
the tumor material was further homogenized using a
QiaShredder column. The RNA was extracted using
RNeasy® Mini Kits (Qiagen, Germantown, MD) following
the manufacturer’s protocol. The tumor cells (5-7 × 106)
were harvested from sub-confluent flasks at passage 4 by
scraping. Following centrifugation, the cell pellets were
flash-frozen in liquid nitrogen and stored at -80°C. RNA
from the cell pellets was isolated using the RNeasy® Mini
Kit following the manufacturer’s protocol.
RNA quantitation and quality control
Following extraction, RNA quantitation was performed
using a Nanodrop spectrophotometer (Thermo Scientific,
Wilmington, DE). Microelectrophoresis was performed on
all samples using an Agilent Bioanalyzer (Santa Clara, CA)
to assess sample quality. The Agilent software algorithm
evaluates the entire electrophoretic trace to estimate the
total RNA integrity in a sample. The algorithm calculates
an RNA Integrity Number (RIN), which classifies the qual-
ity of the RNA on a numeric system from 1 to 10, with 1
being the most degraded and 10 being the most intact. The
RIN number allows comparison of the quality of the RNA
between samples and ensures better reproducibility. In this
study, 73% of RNA samples scored a RIN of >9, while 25%
had a RIN of 7–9 and 2% had a RIN 5.7-7.
Microarray analysis
The RNA samples were submitted to Expression Analysis,
Inc. (Durham, NC) for microarray analysis using the
HG-U133 Plus 2.0 array (Affymetrix, Santa Clara, CA).
Samples were prepared and hybridized according to the
“Affymetrix Technical Manual” (www.expressionanalysis.
com). Following staining of the microarray, the fluorescent
images were detected in a GeneChip® Scanner 3000 and
expression data were extracted using the GeneChip Com-
mand Console Software (AGCC) v 2.0 (Affymetrix). All
GeneChips were scaled to a median intensity setting of500. Raw array (.CEL files) data are available for direct
download from the Developmental Therapeutics Program
(http://dtp.nci.nih.gov/microxeno/download.html) and
from the Gene Expression Omnibus (http://www.ncbi.
nlm.nih.gov/geo/), accessions GSE49353 and GSE48433.
Microarray data were analyzed using the default ‘guided
workflow’ option within Genespring 12.6.1 (Agilent, Santa
Clara, CA). In brief, raw data (.CEL) files were imported and
replicates assigned to relevant conditions (e.g. 786–0 P0).
All data files within the experiment were then normalized
using RMA [39], to generate a spreadsheet containing
log2 normalized gene expression values. Next, probe sets
were filtered with reference to flags [attributes that denote
poor quality entities] along with a percentile cut-off
(20%) - which makes the assumption that 20% of the
probe sets on any given genome-wide array have intensity
values that represent noise (since they are not expressed).
Next, significance was determined by performing one-way
ANOVA p < 0.05. For the remaining observations a fold
change cut-off could then be applied [default +/− 2 fold].
Mouse/human endpoint PCR
As described in Alcoser et al. [14] human- or mouse-
specific forward primers from the prostaglandin E receptor
2 (PTGER2) gene were used to amplify 189 bp fragments,
thereby identifying the presence of mouse DNA and/or
human DNA in each tissue/cell sample. Human-specific
primers: Forward, 5′- gctgcttctcattgtctcgg-3′; Reverse,
5′- gccaggagaatgaggtggtc-3′. Mouse-specific primers:
Forward, 5′- cctgctgcttatcgtggctg-3′; Reverse, 5′- gccag
gagaatgaggtggtc-3′. PCR was performed using neutral-
ized, unpurified tissue/cell lysate on an ABI-2720
Thermocycler (Applied Biosystems). PCR conditions:
95°C-5 min, 30 cycles of (95°C-45 sec, 60°C-30 sec,
72°C-90 sec), 72°C-10 min. DNA bands were resolved on
a 2% agarose gel containing ethidium bromide (0.5 mg/ml).
Identification of probe sets on Affymetrix U133 Plus 2
array with the potential to cross-hybridize with mouse
transcripts
Array data were generated for 5 different mouse RNA
populations hybridized to human Affymetrix U133 Plus
2 chips (3 replicates for each biological sample). The sam-
ples were A) mouse Universal RNA (Strategene, La Jolla,
CA), B) B16F10 murine melanoma tumors, C) skin from
C57BL/6 mice bearing B16F10 tumors, D) colon 26
murine tumors, and E) skin from Balb/C mice bearing
Colon 26 tumors. Mouse RNAs of varied origin were
used to provide a diversity of mouse transcripts for subse-
quent qualitative detection of array binding. The 15 .txt
files generated (5 biological samples, 3 replicates each)
were interrogated and for each sample type, all probe sets
with a PPP, PPM or PPA [P = present, M = marginal,
A = absent] detection call were sorted into a separate
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PPA nomenclature represents 1 array from the tripli-
cate samples. The five lists of probes were combined
into a single file and the Microsoft Excel utility DigDb
[www.Digdb.com] was used to remove redundancy and to
determine how many biological samples contained detect-
able transcript (shown as PPX ID in # Mouse Tissues –
out of five). The resultant list of probe sets and number of
mouse RNA samples in which they are called present
(PPX) can be found in Additional file 7.
Availability of supporting data
The data sets supporting the results of this article are
available for direct download from the Developmental
Therapeutics Program (http://dtp.nci.nih.gov/microxeno/
download.html) and from the Gene Expression Omnibus
(http://www.ncbi.nlm.nih.gov/geo/), accessions GSE49353
and GSE48433 as well as in the Additional Files.Additional files
Additional file 1: Hierarchical clustering of cell line and xenograft
samples. 823 arrays [47 complete models] were uploaded into Genespring
(Agilent, Santa Clara, CA) using the Affymetrix expression guided workflow
and data normalized using RMA. Entities were then assigned and log2 gene
expression data generated for those transcripts that met the following criteria:
percentile cut-off = 20, ANOVA p< 0.05, probe sets must be differentially
expressed +/− 100 fold in 1 group. The probe sets meeting these criteria were
then subjected to Hierarchical clustering according to both conditions [cell
lines/passages] and entities [probe sets] with a Pearson absolute distance
metric and centroid linkage.
Additional file 2: Issues identified during Hierarchical clustering.
Additional file 3: RMA normalized log2 gene expression data for all 49
models - unfiltered, includes all probe sets on the U133 Plus 2.0 Array.
Additional file 4: Antitumor efficacy of paclitaxel against HCT-15
xenografts at passages 1 (P1) and 8 (P8). Vehicle treated mice
received 12.5% cremaphor/12.5% ethanol/75% saline QDx5 IV while
paclitaxel was administered at 10 mg/kg QDx5 IV. Statistically significant
differences between the treated and control mice were determined with
Student’s t-test, those points with significant paclitaxel responses are
designated by showing the p value adjacent to the data point. A) P1
tumors B) P8 tumors.
Additional file 5: Antitumor efficacy of cisplatin against MOLT-4
and A549 xenografts. Vehicle treated mice received 0.9% saline once
every 4 days for 3 treatments (Q4Dx3) by the intraperitoneal (IP) route.
Statistically significant differences between the treated and control mice
were determined with Student’s t-test, those points with significant
cisplatin responses are designated by with the p value adjacent to the
data point A) MOLT-4 xenografts, the cisplatin dose was 3.24 mg/kg. B)
A549 xenografts, the cisplatin dose was 6.7 mg/kg.
Additional file 6: List of transcripts identified as cross-hybridizing
with mouse cDNA.
Additional file 7: Change in expression (log2) across the entire
U133 plus 2 array for all models from P0 to P1 with cross-
hybridizing probe sets shown.
Additional file 8: A) Top 50 up-regulated probe sets in 9 of 13 tumor
types. Left table includes all probe sets, where mouse cross-hybridizing
probe sets are shaded grey. Right table shows the top 50 up-regulated
probe sets following removal of the cross hybridizing component. B) DAVID
gene ontology (GO) functional annotation for each tumor model during
transition from in vitro to in vivo growth.Competing interests
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